RE-KINECT and KINECT 4 studies of Ingrezza in tardive dyskinesia show sustained improvements.- Neurocrine Biosciences.

Neurocrine Biosciences announced new data from RE-KINECT, the largest real-world screening study to date of patients using Ingrezza (valbenazine) with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the impact of involuntary movements on the quality of life of patients taking antipsychotic medication. Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.

Over half of patients with clinician-confirmed possible TD were affected by uncontrollable movements in two or more body regions. Researchers also presented data analyses from the long-term, open-label, Phase III KINECT 4 study demonstrating sustained and clinically meaningful TD improvement in participants with schizophrenia/schizoaffective disorder or mood disorder who had received valbenazine capsules once-daily for up to 48 weeks. Participants diagnosed with schizophrenia/schizoaffective disorder receiving Ingrezza 40 mg or 80 mg once-daily showed a mean improvement, at week 48, from baseline in the Abnormal Involuntary Movement Scale (AIMS) of 10.1 and 10.7 points, respectively, while participants diagnosed with mood disorder showed an improvement of 10.2 and 11.6 points, respectively. Consistent with prior studies, Ingrezza was well tolerated with a safety profile consistent with previous studies.

Additionally, researchers presented baseline characteristics of participants enrolled in the open-label KINECT 4 study. Seventy-three percent of participants in the study had a primary psychiatric diagnosis of schizophrenia / schizoaffective disorder while 27 percent of participants had a mood disorder. These data were presented at the American Psychiatric Association (APA) Annual Meeting.